Evidence map›Paper›PMID 26778234›Full record

ReviewSeminars in perinatology2016

Stem cell-based therapies for the newborn lung and brain: Possibilities and challenges.

S Alex Mitsialis, Stella Kourembanas

Open access · hybridAbstract readReview
In one paragraph

Review in Seminars in perinatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 6 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 6 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Outcomes after intranasal human milk therapy in preterm infants with intraventricular hemorrhage.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

S Alex MitsialisDivision of Newborn Medicine, Boston Children's Hospital, 300 Longwood Ave/Enders 9, Boston, MA 02115; Department of Pediatrics, Harvard Medical School, Boston, MA 02115. Electronic address: Alex.mitsialis@childrens.harvard.edu.
Stella KourembanasDivision of Newborn Medicine, Boston Children's Hospital, 300 Longwood Ave/Enders 9, Boston, MA 02115; Department of Pediatrics, Harvard Medical School, Boston, MA 02115.
Boston Children's Hospital · USHarvard University · US

Funding

Training Program in Newborn and Developmental DiseasesT32HD007466 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI KOUREMBANAS, STELLA · 1994 to 2016
$8.0M
HYPOXIC RESPONSES OF VASCULAR SMOOTH MUSCLER01HL055454 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI KOUREMBANAS, STELLA · 1996 to 2018
$6.7M
Mesenchymal Stem Cells and Pulmonary HypertensionR01HL085446 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KOUREMBANAS, STELLA · 2007 to 2011
$2.1M
NHLBI NIH HHS R01 HL055454NHLBI NIH HHS R01 HL085446NICHD NIH HHS T32 HD007466
6 · The paper itself

Abstract

There have been substantial advances in neonatal medical care over the past 2 decades that have resulted in the increased survival of very low birth weight infants, survival that in some centers extends to 22 weeks gestational age. Despite these advances, there continues to be significant morbidity associated with extreme preterm birth that includes both short-term and long-term pulmonary and neurologic consequences. No single therapy has proven to be effective in preventing or treating either developmental lung and brain injuries in preterm infants or the hypoxic-ischemic injury that can be inflicted on the full-term brain as a result of in utero or perinatal complications. Stem cell-based therapies are emerging as a potential paradigm-shifting approach for such complex diseases with multifactorial etiologies, but a great deal of work is still required to understand the role of stem/progenitor cells in normal development and in the repair of injured tissue. This review will summarize the biology of the various stem/progenitor cells, their effects on tissue repair in experimental models of lung and brain injury, the recent advances in our understanding of their mechanism of action, and the challenges that remain to be addressed before their eventual application to clinical care.

Indexed as

Bronchopulmonary DysplasiaHypoxia-Ischemia, BrainStem CellsStem Cell TransplantationExosomesHumansInfant, NewbornInfant, PrematureInfant, Very Low Birth WeightLong Term Adverse EffectsModels, TheoreticalOutcome and Process Assessment, Health CareBronchopulmonary dysplasiaExosomesHypoxic-ischemic encephalopatyMesenchymal stem cells

Identifiers

PMID26778234
PMCPMC4808378
OpenAlexW2267514764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.